{
    "hands_on_practices": [
        {
            "introduction": "One of the most direct mechanisms for a gain-of-function effect is an increase in the abundance of a protein. This practice problem guides you through a fundamental kinetic model to quantify how a mutation that increases a protein's half-life results in a higher steady-state concentration. Mastering this concept is key to understanding how defects in protein degradation pathways can lead to disease .",
            "id": "5033642",
            "problem": "A gain-of-function mutation in a signaling protein removes a degron that is normally recognized by the Ubiquitin-Proteasome System (UPS), selectively impairing protein turnover without affecting transcription or translation. In a stable cell line where transcription and translation are constant, model the intracellular protein concentration $P(t)$ by a mass-balance with constant synthesis rate $k_s$ (units of concentration per hour) and first-order degradation with rate constant $k_d$ (units of per hour). The wild-type protein has a half-life of $2$ h, while the mutant has a half-life of $8$ h. Assume the cell has reached steady state under the mutant condition.\n\nStarting only from the Central Dogma of Molecular Biology (DNA $\\to$ RNA $\\to$ protein) as a statement that synthesis can be approximated as a constant input for a constitutively expressed gene, the standard first-order decay law for unimolecular processes, and the definition of half-life under first-order kinetics, derive the steady-state concentration $P_{\\mathrm{ss,mut}}$ for the mutant protein in terms of $k_s$ and fundamental constants. Express your final answer as a closed-form analytical expression in terms of $k_s$ and standard mathematical constants. Do not include units in your final boxed answer. Assume time is measured in hours and $k_s$ is measured in concentration per hour.",
            "solution": "The problem requires the derivation of the steady-state concentration of a mutant protein, denoted as $P_{\\mathrm{ss,mut}}$. The derivation must start from fundamental principles and use the provided parameters.\n\n### Problem Validation\n\n**Step 1: Extraction of Givens**\n*   **Model:** The intracellular protein concentration $P(t)$ is modeled by a mass-balance with a constant synthesis rate $k_s$ (concentration/hour) and first-order degradation with rate constant $k_d$ (1/hour). The governing equation is effectively $\\frac{dP(t)}{dt} = k_s - k_d P(t)$.\n*   **Wild-Type Half-Life:** $t_{1/2, \\text{wt}} = 2$ h.\n*   **Mutant Half-Life:** $t_{1/2, \\text{mut}} = 8$ h.\n*   **Condition:** The system has reached steady state under the mutant condition.\n*   **Starting Principles:** Central Dogma (justifying constant $k_s$), standard first-order decay law, and the definition of half-life under first-order kinetics.\n*   **Objective:** Derive the steady-state concentration $P_{\\mathrm{ss,mut}}$ for the mutant protein as a closed-form analytical expression in terms of $k_s$ and standard mathematical constants.\n\n**Step 2: Validation against Criteria**\n*   **Scientific Grounding (Critical):** The problem is scientifically sound. It describes protein turnover regulation via the Ubiquitin-Proteasome System (UPS) and models the kinetics using a standard mass-action approach (zero-order synthesis, first-order decay). This is a fundamental and widely used model in quantitative cell biology and biochemistry. The described biological scenario—a gain-of-function mutation that removes a degron sequence, leading to increased protein stability (and thus a longer half-life)—is a well-established molecular mechanism.\n*   **Well-Posed:** The problem is well-posed. It supplies a clear mathematical framework, sufficient parameters to determine the model's coefficients for the mutant protein (i.e., $t_{1/2, \\text{mut}}$), and a specific condition (steady state) from which a unique solution for the requested variable ($P_{\\mathrm{ss,mut}}$) can be determined.\n*   **Objective (Critical):** The problem is stated using precise, unambiguous, and objective scientific terminology.\n*   **Completeness and Consistency:** The problem is self-contained. The assumption of constant transcription and translation provides a physical basis for the constant synthesis rate $k_s$. The increase in half-life from $2$ h to $8$ h is consistent with the described mutation that impairs protein degradation. The information about the wild-type half-life ($t_{1/2, \\text{wt}}$) is extraneous for calculating the mutant's steady-state concentration but does not introduce any contradiction.\n*   **Other Flaws:** The problem does not exhibit any other flaws. It is not unrealistic, ill-posed, trivial, or based on unverifiable claims. It constitutes a standard exercise in applying principles of chemical kinetics to a biological system.\n\n**Step 3: Verdict**\n*   The problem is **valid**. The solution process will now proceed.\n\n### Derivation of the Solution\n\nThe dynamics of the protein concentration, $P(t)$, are governed by the linear, first-order ordinary differential equation based on the specified mass-balance model:\n$$\n\\frac{dP(t)}{dt} = k_s - k_d P(t)\n$$\nIn this equation, $k_s$ represents the constant rate of protein synthesis (modeled as a zero-order process), and the term $k_d P(t)$ represents the rate of protein degradation (modeled as a first-order process with rate constant $k_d$).\n\nThe problem states that the cell line has reached steady state with the mutant protein. At steady state, the concentration of the protein is, by definition, constant. Therefore, the time derivative of the concentration is zero:\n$$\n\\frac{dP(t)}{dt} = 0\n$$\nLet $P_{\\mathrm{ss,mut}}$ be the steady-state concentration of the mutant protein and $k_{d, \\text{mut}}$ be its specific degradation rate constant. Applying the steady-state condition to the governing equation for the mutant protein gives:\n$$\n0 = k_s - k_{d, \\text{mut}} P_{\\mathrm{ss,mut}}\n$$\nSolving for $P_{\\mathrm{ss,mut}}$ yields the general expression for the steady-state concentration:\n$$\nP_{\\mathrm{ss,mut}} = \\frac{k_s}{k_{d, \\text{mut}}}\n$$\nThis equation shows that the steady-state concentration is determined by the ratio of the synthesis rate to the degradation rate constant.\n\nThe next step, as dictated by the problem statement, is to relate the degradation rate constant $k_d$ to the protein's half-life $t_{1/2}$ using the definition of first-order decay. For a substance undergoing first-order decay from an initial concentration $P_0$ (in the absence of synthesis), the concentration at time $t$ is given by the law of unimolecular processes:\n$$\nP(t) = P_0 \\exp(-k_d t)\n$$\nThe half-life, $t_{1/2}$, is defined as the time required for the concentration to decrease to one-half of its initial value, such that $P(t_{1/2}) = \\frac{P_0}{2}$. Substituting this definition into the decay equation:\n$$\n\\frac{P_0}{2} = P_0 \\exp(-k_d t_{1/2})\n$$\nDividing by $P_0$ (where $P_0 \\neq 0$):\n$$\n\\frac{1}{2} = \\exp(-k_d t_{1/2})\n$$\nTo solve for $k_d$, we take the natural logarithm of both sides of the equation:\n$$\n\\ln\\left(\\frac{1}{2}\\right) = \\ln(\\exp(-k_d t_{1/2})) = -k_d t_{1/2}\n$$\nUsing the logarithm property $\\ln(1/x) = -\\ln(x)$, this becomes:\n$$\n-\\ln(2) = -k_d t_{1/2}\n$$\nTherefore, the relationship between the first-order rate constant and half-life is:\n$$\nk_d = \\frac{\\ln(2)}{t_{1/2}}\n$$\nWe apply this relationship to the mutant protein. The problem provides the half-life of the mutant protein as $t_{1/2, \\text{mut}} = 8$ h. The corresponding degradation rate constant, $k_{d, \\text{mut}}$, is:\n$$\nk_{d, \\text{mut}} = \\frac{\\ln(2)}{t_{1/2, \\text{mut}}} = \\frac{\\ln(2)}{8}\n$$\nThe units of $k_{d, \\text{mut}}$ are hours$^{-1}$, which is dimensionally consistent. The synthesis rate $k_s$ is stated to be unaffected by the mutation.\n\nFinally, we substitute the expression for $k_{d, \\text{mut}}$ into our equation for the steady-state concentration $P_{\\mathrm{ss,mut}}$:\n$$\nP_{\\mathrm{ss,mut}} = \\frac{k_s}{k_{d, \\text{mut}}} = \\frac{k_s}{\\frac{\\ln(2)}{8}}\n$$\nBy algebraic manipulation, we arrive at the final closed-form analytical expression for the steady-state concentration of the mutant protein in terms of $k_s$ and the standard mathematical constant $\\ln(2)$:\n$$\nP_{\\mathrm{ss,mut}} = \\frac{8k_s}{\\ln(2)}\n$$",
            "answer": "$$\\boxed{\\frac{8k_s}{\\ln(2)}}$$"
        },
        {
            "introduction": "Gain-of-function can also arise from mutations that alter a protein's structure, for instance, by removing a regulatory domain. This exercise presents a clinical scenario where a premature termination codon surprisingly leads to a hyperactive protein, challenging you to integrate principles of mRNA surveillance (Nonsense-Mediated Decay) with protein structure-function relationships. Solving this case study will sharpen your ability to deduce molecular mechanisms from genetic and biochemical data .",
            "id": "5033628",
            "problem": "A patient carries a heterozygous single-nucleotide variant in a cytosolic kinase gene, Gene $X$, which has $12$ exons. The variant introduces a premature termination codon (PTC) at amino acid $1050$ within exon $12$ (the last exon). Quantitative reverse transcription polymerase chain reaction (qRT-PCR) shows Gene $X$ messenger ribonucleic acid (mRNA) abundance in patient lymphoblasts is approximately unchanged relative to controls (patient/control ratio $\\approx 0.95$–$1.05$). Ribosome profiling and immunoblotting with an antibody recognizing an $N$-terminal epitope detect a truncated Gene $X$ protein consistent with translation terminating at the PTC. RNA sequencing reveals exon-exon junction read counts and splicing patterns indistinguishable from controls. The $3'$ untranslated region ($3'$ UTR) of Gene $X$ is of typical length for human mRNAs (approximately $600$ nucleotides). In vitro kinase assays demonstrate that patient cells exhibit a $\\sim 4$-fold increase in Gene $X$ catalytic activity relative to control cells. Prior biochemical characterization of Gene $X$ has established that its distal C-terminal tail encodes an autoinhibitory motif that restrains kinase activity by intramolecular interaction with the catalytic domain.\n\nStarting from the Central Dogma of molecular biology (deoxyribonucleic acid $\\rightarrow$ ribonucleic acid $\\rightarrow$ protein) and widely accepted principles of eukaryotic translation termination and mRNA surveillance, reason about the fate of transcripts harboring PTCs and the functional consequences of truncations affecting autoinhibitory domains. Which option best explains both the escape of the PTC-containing mRNA from nonsense-mediated decay and the observed gain-of-function phenotype?\n\nA. The premature termination codon lies in the last exon; without any downstream exon junction complex (EJC), the termination event is not recognized by nonsense-mediated decay (NMD), allowing the transcript to remain stable and be translated. The truncation removes the C-terminal autoinhibitory tail, eliminating intramolecular inhibition and producing a gain-of-function.\n\nB. Nonsense-associated altered splicing skips the last exon, restoring the reading frame and producing a full-length protein with hyperactivity.\n\nC. The premature termination codon triggers nonstop decay, which enhances translation and stabilizes truncated proteins, explaining the gain-of-function.\n\nD. Translation reinitiation at a downstream start codon generates an in-frame C-terminal fragment that binds and activates the full-length protein, explaining the gain-of-function without truncation.\n\nE. Upregulated nonsense-mediated decay of last-exon premature termination codons reduces mRNA levels, but the truncated protein accumulates because the proteasome cannot recognize premature termination products, yielding a gain-of-function.",
            "solution": "The user wants me to solve the following problem based on the provided text.\n\n### Step 1: Extract Givens\n\n- **Genetic Context:** A patient is heterozygous for a single-nucleotide variant in `Gene X`.\n- **Gene Structure:** `Gene X` is a cytosolic kinase gene with $12$ exons.\n- **Mutation Details:** The variant creates a premature termination codon (PTC) at amino acid position $1050$. This PTC is located within exon $12$, which is the last exon.\n- **mRNA Abundance:** Quantitative reverse transcription polymerase chain reaction (qRT-PCR) shows the total `Gene X` mRNA level in patient cells is comparable to control cells (patient/control ratio $\\approx 0.95$–$1.05$).\n- **Protein Product:** Ribosome profiling and immunoblotting (using an $N$-terminal antibody) confirm the presence of a truncated `Gene X` protein, consistent in size with translation ending at the PTC.\n- **Splicing Pattern:** RNA sequencing indicates that exon-exon junction counts and overall splicing patterns are normal and indistinguishable from controls.\n- **Gene Architecture:** The $3'$ untranslated region ($3'$ UTR) of `Gene X` has a typical length of approximately $600$ nucleotides.\n- **Functional Consequence:** In vitro kinase assays show that the total `Gene X` catalytic activity in patient cells is increased by approximately $4$-fold compared to control cells, indicating a gain-of-function.\n- **Protein Regulation:** The distal C-terminal tail of the wild-type `Gene X` protein contains an autoinhibitory motif.\n\n### Step 2: Validate Using Extracted Givens\n\n- **Scientific Groundedness:** The problem is firmly rooted in established principles of molecular biology, genetics, and biochemistry. The concepts of heterozygosity, exons, premature termination codons (PTCs), mRNA surveillance (specifically, nonsense-mediated decay or NMD), translation, protein domains (catalytic, autoinhibitory), and standard molecular biology techniques (qRT-PCR, immunoblotting, RNA-seq) are all fundamental and accurately represented. The described scenario—a gain-of-function resulting from the truncation of an autoinhibitory domain due to a PTC that evades NMD—is a known mechanism in human genetic disease.\n- **Well-Posed:** The problem is well-posed. It provides a comprehensive set of experimental data and asks for the single best mechanistic explanation that is consistent with all the observations. The provided data are sufficient to logically deduce the correct mechanism and rule out the alternatives.\n- **Objectivity:** The problem is stated using precise, objective scientific language. It presents experimental results as facts and asks for a reasoned explanation based on those facts. There are no subjective or opinion-based elements.\n- **Completeness and Consistency:** The problem is self-contained and internally consistent. The observation of normal mRNA levels (via qRT-PCR) despite a PTC is a key puzzle piece that must be explained. The location of the PTC in the final exon is critical information for resolving this puzzle. The detection of a truncated protein (immunoblot) and increased kinase activity (assay) are consistent with the known function of the C-terminal domain. The RNA-seq data serves to rule out alternative splicing-based mechanisms. All data points converge on a single, coherent explanation.\n- **Realism and Feasibility:** The scenario is highly realistic. The qRT-PCR ratio, the gene structure, and the functional outcome are all plausible and representative of real-world biological systems.\n- **Structure and Triviality:** The problem is well-structured, requiring the integration of knowledge from different areas of molecular cell biology. It is not trivial, as it requires a precise understanding of the rules governing nonsense-mediated decay.\n\n### Step 3: Verdict and Action\n\nThe problem statement is **valid** as it is scientifically sound, well-posed, objective, and internally consistent. I will now proceed to derive the solution.\n\n### Derivation of the Correct Answer\n\nThe problem requires an explanation for two key observations in the patient: $1)$ the stability of the mutant mRNA transcript and $2)$ the gain-of-function phenotype of increased kinase activity.\n\n1.  **Fate of the PTC-Containing Transcript and Nonsense-Mediated Decay (NMD):**\n    The Central Dogma states that genetic information flows from DNA to RNA to protein. In eukaryotes, transcripts containing PTCs are typically targeted for degradation by the NMD pathway. The canonical mechanism of NMD activation involves the recognition of a termination codon as premature. This recognition generally depends on the position of the stop codon relative to downstream exon junction complexes (EJCs). EJCs are protein complexes deposited approximately $20$-$24$ nucleotides upstream of exon-exon junctions during pre-mRNA splicing. During the first, or \"pioneer,\" round of translation, if the ribosome terminates translation and dissociates at a stop codon located more than $\\sim 50$-$55$ nucleotides upstream of a downstream EJC, the EJC will recruit NMD factors (like UPF1, UPF2, UPF3) that trigger the degradation of the mRNA.\n\n    In this problem, the PTC is located in exon $12$, the **last exon**. Splicing joins exons $1$ through $12$, leaving the final exon-exon junction between exon $11$ and exon $12$. Since the PTC is within the final exon, there are no subsequent downstream splicing events and therefore **no downstream EJCs**. Consequently, when the ribosome terminates at this PTC, the cell's surveillance machinery does not recognize the termination event as \"premature\" in the context of the NMD pathway. The termination is treated as if it were a normal stop codon, and the mRNA is protected from NMD.\n\n    This theoretical conclusion is strongly supported by the experimental data. The qRT-PCR results show that the total `Gene X` mRNA abundance is near normal (patient/control ratio $\\approx 1.0$). If the mutant transcript were efficiently degraded by NMD, one would expect the total mRNA level in the heterozygous patient to be reduced to approximately $50$% of the control level. The observed normal mRNA level confirms that the PTC-containing transcript is stable and escapes NMD.\n\n2.  **Functional Consequences of the Truncation:**\n    Since the mutant mRNA is stable, it is translated into protein. Translation proceeds from the start codon and terminates at the PTC at amino acid $1050$. This produces a truncated protein that lacks the amino acids encoded downstream of this position. The problem states that the distal C-terminal tail of `Gene X` normally encodes an autoinhibitory motif that restrains the kinase's catalytic activity. The truncation caused by the PTC removes this autoinhibitory domain. The resulting protein, while shorter, retains its N-terminal portion, which includes the catalytic kinase domain. Without the inhibitory C-terminal tail, the kinase domain is constitutively active or hyperactive.\n\n    The patient is heterozygous, meaning their cells produce both the full-length, normally regulated wild-type protein and the truncated, hyperactive mutant protein. The total kinase activity in the cell is the sum of the activities from both protein populations. The presence of the hyperactive truncated protein leads to an overall increase in cellular kinase activity. This is perfectly consistent with the kinase assay data showing a $\\sim 4$-fold increase in activity, which defines the gain-of-function phenotype. The immunoblotting data confirms the expression of this truncated protein.\n\n### Evaluation of Options\n\n**A. The premature termination codon lies in the last exon; without any downstream exon junction complex (EJC), the termination event is not recognized by nonsense-mediated decay (NMD), allowing the transcript to remain stable and be translated. The truncation removes the C-terminal autoinhibitory tail, eliminating intramolecular inhibition and producing a gain-of-function.**\nThis option accurately describes the two key parts of the mechanism derived above. It correctly identifies the reason for NMD escape (PTC in the last exon, no downstream EJC) and the reason for the gain-of-function (truncation removing an autoinhibitory domain). This is consistent with all provided data.\n**Verdict: Correct.**\n\n**B. Nonsense-associated altered splicing skips the last exon, restoring the reading frame and producing a full-length protein with hyperactivity.**\nThis option is contradicted by two key pieces of evidence. First, the RNA sequencing data explicitly states that \"splicing patterns [are] indistinguishable from controls,\" ruling out altered splicing. Second, ribosome profiling and immunoblotting detect a *truncated* protein, not a rearranged full-length protein.\n**Verdict: Incorrect.**\n\n**C. The premature termination codon triggers nonstop decay, which enhances translation and stabilizes truncated proteins, explaining the gain-of-function.**\nThis option misidentifies the relevant mRNA quality control pathway. Nonstop decay (NSD) targets mRNAs that *lack* a stop codon, not those with a premature one. Furthermore, NSD leads to mRNA and protein *degradation*, not stabilization or enhanced translation.\n**Verdict: Incorrect.**\n\n**D. Translation reinitiation at a downstream start codon generates an in-frame C-terminal fragment that binds and activates the full-length protein, explaining the gain-of-function without truncation.**\nThis option is inconsistent with the data. The problem explicitly states that a *truncated* protein is detected, which is the direct product of termination at the PTC. This option proposes a mechanism \"without truncation,\" which is factually wrong based on the immunoblotting evidence. While reinitiation is a possible event, the primary and confirmed molecular species is the N-terminally truncated protein, which must be accounted for in the explanation.\n**Verdict: Incorrect.**\n\n**E. Upregulated nonsense-mediated decay of last-exon premature termination codons reduces mRNA levels, but the truncated protein accumulates because the proteasome cannot recognize premature termination products, yielding a gain-of-function.**\nThis option contains multiple falsehoods. First, as a general rule, PTCs in the last exon *escape* NMD, they do not trigger \"upregulated\" NMD. This is directly contradicted by the qRT-PCR data showing normal mRNA levels. Second, the claim that proteasomes cannot recognize premature termination products is a baseless generalization; improperly folded or incomplete proteins are often prime targets for proteasomal degradation.\n**Verdict: Incorrect.**",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Understanding a genetic disorder requires bridging the gap from the molecular mechanism to its impact on a population. This problem asks you to apply the Hardy-Weinberg equilibrium principle to a dominant gain-of-function disorder with incomplete penetrance, a common scenario in medical genetics. By deriving the disease prevalence, you will practice connecting allele frequencies and clinical parameters to predict population-level outcomes .",
            "id": "5033594",
            "problem": "Consider a monogenic disorder caused by a gain-of-function (GOF) variant in a receptor tyrosine kinase gene that leads to ligand-independent signaling. In a large, randomly mating population at Hardy–Weinberg equilibrium (HWE), assume no migration, mutation, or selection for or against any genotype in the current generation. Let the population allele frequency of the GOF variant be $q$, and let the wild-type allele frequency be $p$. Assume the GOF variant acts in a genetically dominant manner, meaning any individual with at least one GOF allele has biological potential for disease manifestation. Due to incomplete penetrance arising from variable downstream pathway thresholds, let the penetrance, defined as the probability that an individual with at least one GOF allele manifests the disease phenotype, be $\\pi$ and assume it is the same for heterozygotes and homozygotes because the biochemical mechanism saturates downstream signaling in both genotypes.\n\nUsing only these assumptions and the definitions of allele frequency, genotype frequency, dominance, and penetrance, derive the expected disease prevalence in the population as an analytic expression in terms of $\\pi$ and $q$. Express the final prevalence as a decimal fraction (not a percentage) and provide the result as a single closed-form expression. No rounding is required.",
            "solution": "The problem statement has been validated and is deemed valid. It is scientifically grounded in the principles of population genetics, specifically the Hardy–Weinberg equilibrium (HWE), and is well-posed, providing all necessary information for a unique, analytical solution. The problem is free of contradictions, ambiguities, and factual unsoundness.\n\nThe objective is to derive the expected disease prevalence in a population, given the allele frequency of a dominant gain-of-function (GOF) variant and its incomplete penetrance.\n\nLet the wild-type allele be denoted by $A$ and the GOF variant allele be denoted by $a$.\nAccording to the problem statement, the frequencies of these alleles in the population are:\nFrequency of the wild-type allele $A$: $p$\nFrequency of the GOF allele $a$: $q$\n\nFor a biallelic locus, the sum of the allele frequencies must be unity:\n$$p + q = 1$$\n\nThe population is stated to be in Hardy–Weinberg equilibrium (HWE). Under HWE, the frequencies of the three possible genotypes ($AA$, $Aa$, and $aa$) are given by the terms of the binomial expansion $(p+q)^2 = p^2 + 2pq + q^2 = 1$.\nThe genotype frequencies are:\n1.  Frequency of wild-type homozygotes ($AA$): $f(AA) = p^2$\n2.  Frequency of heterozygotes ($Aa$): $f(Aa) = 2pq$\n3.  Frequency of GOF homozygotes ($aa$): $f(aa) = q^2$\n\nThe disease is caused by the GOF allele $a$, which acts in a genetically dominant manner. This means that individuals with at least one copy of the $a$ allele are genetically predisposed to the disease. The genotypes associated with this predisposition are the heterozygote $Aa$ and the GOF homozygote $aa$. Individuals with the $AA$ genotype do not carry the GOF allele and thus will not develop this specific monogenic disorder.\n\nPenetrance, denoted by $\\pi$, is the probability that an individual with a predisposing genotype will manifest the associated phenotype (the disease). The problem states that the penetrance is $\\pi$ for any individual with at least one GOF allele. This means the probability of disease manifestation is the same for both $Aa$ and $aa$ genotypes.\n-   The probability that an individual with genotype $AA$ manifests the disease is $0$.\n-   The probability that an individual with genotype $Aa$ manifests the disease is $\\pi$.\n-   The probability that an individual with genotype $aa$ manifests the disease is $\\pi$.\n\nThe overall disease prevalence in the population is the sum of the products of each genotype's frequency and its corresponding penetrance.\nPrevalence = $[f(AA) \\times P(\\text{disease}|AA)] + [f(Aa) \\times P(\\text{disease}|Aa)] + [f(aa) \\times P(\\text{disease}|aa)]$\n\nSubstituting the genotype frequencies from HWE and the given penetrance values:\nPrevalence = $(p^2 \\times 0) + (2pq \\times \\pi) + (q^2 \\times \\pi)$\n\nSimplifying the expression:\nPrevalence = $0 + 2pq\\pi + q^2\\pi$\nPrevalence = $\\pi (2pq + q^2)$\n\nThe problem requires the final expression to be in terms of $\\pi$ and $q$ only. To achieve this, we use the relationship $p = 1 - q$ and substitute it into the prevalence expression.\nPrevalence = $\\pi (2(1-q)q + q^2)$\n\nExpanding the terms inside the parentheses:\nPrevalence = $\\pi (2q - 2q^2 + q^2)$\n\nCombining the terms in $q^2$:\nPrevalence = $\\pi (2q - q^2)$\n\nThis is the final, closed-form analytic expression for the disease prevalence in the population as a function of the GOF allele frequency $q$ and the penetrance $\\pi$.\n\nAs a verification, an alternative approach is to first calculate the total frequency of individuals carrying at least one GOF allele.\nFrequency of at-risk genotypes = $f(Aa) + f(aa) = 2pq + q^2$.\nUsing the identity $p^2 + 2pq + q^2 = 1$, we can write this as $1 - p^2$.\nSubstituting $p = 1-q$:\nFrequency of at-risk genotypes = $1 - (1-q)^2 = 1 - (1 - 2q + q^2) = 2q - q^2$.\nSince all individuals in this group have a probability $\\pi$ of manifesting the disease, the total prevalence is the frequency of this group multiplied by the penetrance:\nPrevalence = $(2q - q^2) \\times \\pi$.\nThis confirms the previous derivation.",
            "answer": "$$\\boxed{\\pi(2q - q^2)}$$"
        }
    ]
}